Document Report Card

Basic Information

ID: ALA4665716

Journal: Bioorg Med Chem Lett

Title: Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.

Authors: Kawatkar SP,Barlaam B,Kemmitt P,Simpson I,Watson D,Wang P,Lamont S,Su Q,Boiko S,Ikeda T,Patel J,Pike A,Pollard H,Read J,Sarkar U,Wang H,Wen Q,Yan Z,Dowling JE,Dry H,Edmondson SD

Abstract: Spleen Tyrosine Kinase (SYK) is a well-studied enzyme with therapeutic applications in oncology and autoimmune diseases. We identified an azabenzimidazole (ABI) series of SYK inhibitors by mining activity data of 86,000 compounds from legacy biochemical assays with SYK and other homologous kinases as target enzymes. A structure-based design and hybridization approach was then used to improve the potency and kinase selectivity of the hits. Lead compound 23 from this novel ABI series has a SYK IC = 0.21 nM in a biochemical assay and inhibits growth of SUDHL-4 cells at a GI = 210 nM.

CiteXplore: 32721854

DOI: 10.1016/j.bmcl.2020.127393